Recently, a phase III clinical trial (NCT04303780) uncovered that AMG-510 significantly increased progression-free survival compared with docetaxel in patients with advanced NSCLC with the KRAS G12C mutation [33]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.